Oncological Efficacy and Safety of Minimally Invasive Focal and Whole-Gland Interventions in the Treatment of Low- and Intermediate-Risk Prostate Cancer : A Systematic Review and Meta-Analysis

Skribek, Benjamin [Skribek, Benjamin (Radiológia), author] Intervenciós Radiológiai Tanszék (SU / FM / C); Centre for Translational Medicine (SU / KSZE); Szabó, Anett [Szabó, Anett (urológia, andrológia), author] Centre for Translational Medicine (SU / KSZE); Department of Urology (SU / FM / C); Ács, Júlia [Ács, Júlia (Urológia), author] Centre for Translational Medicine (SU / KSZE); Department of Urology (SU / FM / C); Cavalcante, Bianca Golzio Navarro [Golzio Navarro Cavalcante, Bianca (Clinical Medicine), author] Department of Oral Biology (SU / FD); Centre for Translational Medicine (SU / KSZE); Sipos, Boglárka Dorina; Hegyi, Péter [Hegyi, Péter (Gasztroenterológia), author] Institute for Translational Medicine (UP / UPMS); Institute of Pancreatic Diseases (SU / FM / C); Centre for Translational Medicine (SU / KSZE); Mátrai, Péter [Mátrai, Péter (Statisztika), author] Institute for Translational Medicine (UP / UPMS); Nyirády, Péter [Nyirády, Péter (Urológia), author] Centre for Translational Medicine (SU / KSZE); Department of Urology (SU / FM / C); Ács, Nándor [Ács, Nándor (Szülészet-nőgyógy...), author] Department of Obsterics and Gynecology Üllői St... (SU / FM / C / DOG); Centre for Translational Medicine (SU / KSZE); Majoros, Attila [Majoros, Attila (urológia), author] Department of Urology (SU / FM / C); Centre for Translational Medicine (SU / KSZE); Deák, Pál Ákos ✉ [Deák, Pál Ákos (radiológia), author] Intervenciós Radiológiai Tanszék (SU / FM / C); Centre for Translational Medicine (SU / KSZE)

English Survey paper (Journal Article) Scientific
Published: CANCERS 2072-6694 17 (17) Paper: 2863 , 22 p. 2025
  • SJR Scopus - Oncology: Q1
Identifiers
Minimally invasive interventions, including irreversible electroporation (IRE), cryoablation, and high-intensity focused ultrasound (HIFU), offer promising alternatives for the treatment of low- and intermediate-risk prostate cancer. We aimed to evaluate the oncological efficacy and safety of these treatments.A systematic search of MEDLINE, Central, and EMBASE was conducted up to 5 January 2025, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Recurrence, complication, survival, biochemical, and retreatment rates were evaluated, with risk of bias assessed using the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) and Risk of Bias 2 (RoB2) tools.85 studies met the inclusion criteria, comprising 42 prospective cohort studies, 36 retrospective cohort studies, six registries, and one randomized controlled trial. Whole-gland HIFU showed significantly lower recurrence (15%) and postoperative mean PSA levels (0.68 ng/mL) than focal HIFU (24%, 2.81 ng/mL). Recurrence rates were similar for focal vs. extended IRE (30% vs. 26%) and focal vs. whole-gland cryoablation (18% vs. 13%). In-field and out-of-field recurrence rates were similar across treatment modalities (5-15%). Retreatment rates were low, with 6-7% of patients receiving a second ablation and 2-8% progressing to radical or hormonal therapy. Major complications were consistently rare. One-year biochemical recurrence-free survival (BRFS) exceeded 95%, and five-year BRFS approached 80% for HIFU and cryoablation.Minimally invasive focal and whole-gland therapies are safe and effective for treating low- and intermediate-risk prostate cancer, with high survival and low major complication rates. Notably, whole-gland HIFU achieves superior biochemical control and lower recurrence than focal HIFU, emphasizing the clinical importance of treatment extent.
Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
2026-10-10 17:02